- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Preference for generic or brand name drugs by U.S. consumers 2014
Preference for generic or brand name drugs by U.S. consumers 2014
If you had a choice between getting a brand name prescription drug or a generic drug, how often would you choose one over the other?
by Statista Research Department,
last edited
Mar 17, 2015
This statistic depicts the preference for generic or brand name drugs by U.S. consumers in 2014. The survey revealed that 42 percent of the respondents would always choose to buy generic drugs over brand name drugs.
If you had a choice between getting a brand name prescription drug or a generic drug, how often would you choose one over the other?
Loading statistic...
| Preference | Share of respondents |
|---|---|
| I would always choose to buy generic drugs over brand name | 42% |
| I would much more often choose to buy generic drugs than brand name | 25% |
| I would somewhat more often choose to buy generic drugs than brand name | 15% |
| I would somewhat more often choose to buy brand name drugs than generic | 9% |
| I would much more often choose to buy brand name drugs than generic | 4% |
| I would always choose to buy brand name prescription drugs over generic | 6% |
| Preference | Share of respondents |
|---|---|
| I would always choose to buy generic drugs over brand name | 42% |
| I would much more often choose to buy generic drugs than brand name | 25% |
| I would somewhat more often choose to buy generic drugs than brand name | 15% |
| I would somewhat more often choose to buy brand name drugs than generic | 9% |
| I would much more often choose to buy brand name drugs than generic | 4% |
| I would always choose to buy brand name prescription drugs over generic | 6% |
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
by Statista Research Department,
last edited
Mar 17, 2015
This statistic depicts the preference for generic or brand name drugs by U.S. consumers in 2014. The survey revealed that 42 percent of the respondents would always choose to buy generic drugs over brand name drugs.
- Show sources information
- As a Premium user you get access to the detailed source references and background information about this statistic.
- Show publisher information
- Release date
- March 2015
- Region
- United States
- Survey time period
- November 12-17, 2014
- Number of respondents
- 2,255 respondents
- Age group
- 18 years and older
- Special properties
- those who purchase prescription drugs
- Method of interview
- Online survey
- Supplementary notes
- Percentages may not add up to 100 percent due to rounding.
Source
- Show sources information
- As a Premium user you get access to the detailed source references and background information about this statistic.
- Show publisher information
- Release date
- March 2015
More information
- Region
- United States
- Survey time period
- November 12-17, 2014
- Number of respondents
- 2,255 respondents
- Age group
- 18 years and older
- Special properties
- those who purchase prescription drugs
- Method of interview
- Online survey
- Supplementary notes
- Percentages may not add up to 100 percent due to rounding.
Other statistics on the topic
+Pharmaceutical Products & Market
Research and development in European pharmaceutical industry by country 2017
+Pharmaceutical Products & Market
VAT rate on prescription-only drugs in Europe 2018
+Pharmaceutical Products & Market
Leading 18 European pharmaceutical companies by retail sales 2015
Pharmaceutical Products & Market
Market share of generics in European countries 2017
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.Marlene Greenfield
Vice President, Hearst Magazines
Statistics on "Pharmaceutical trends in Europe"
- Overview
The most important statistics
- Turnover of leading pharmaceutical markets in Europe in 2017 (in million euros)Turnover of leading European pharmaceutical markets 2017
- Turnover of pharmaceutical markets in Central and Eastern Europe in 2017 (in million euros)Turnover of pharmaceutical markets in Central and Eastern Europe 2017
- Share of breakdown of pharmaceutical price structure in Europe in 2016*Pharmaceutical price structure breakdown in Europe 2016
- Value Added Tax (VAT) rate on over-the-counter (OTC) drugs in Europe in 2018, by country*VAT rate on over-the-counter drugs in Europe 2018, by country
- Value Added Tax (VAT) rate on prescription-only drugs in Europe in 2018, by countryVAT rate on prescription-only drugs in Europe 2018
- Share of GDP expenditure on research and development in the EU-28 countries from 2000 to 2017*European Union: share of GDP expenditure on research and development 2000-2017
- Pharmaceutical research and development spending in selected European countries in 2017 (in million euros)Research and development in European pharmaceutical industry by country 2017
- Annual growth of pharmaceutical R&D spending in Europe and the U.S. between 2004 and 2018Yearly growth rate of R&D spending in pharmaceutical industry 2004-2018
- European Pharmaceutical companies
The most important statistics
- Leading 18 European pharmaceutical companies by retail sales in 2015 (in billion U.S. dollars)Leading 18 European pharmaceutical companies by retail sales 2015
- Leading pharmaceutical and biotechnology companies in Europe in 2015, based on market value (in million U.S. dollars)Leading European pharmaceutical & biotechnology companies ranked by market value 2015
- Leading European pharmaceutical companies by spending on research and development in 2015 (in million U.S. dollars)Leading European pharmaceutical companies by R&D spending 2015
- Leading European pharmaceutical companies by investment in research and development in 2014 (in million U.S. dollars)Leading European pharmaceutical companies by R&D investment 2014
- Pharmaceutical production value of EFPIA members from 1990 to 2018 (in million euros)Members of EFPIA's pharmaceutical production value 1990-2018
- Pharmaceutical research and development spending of EFPIA members from 1990 to 2018 (in million euros)Members of EFPIA's pharmaceutical R&D spending 1990-2018
- Self-medication market
The most important statistics
- Sales in the self-medication market in selected European countries in 2017 (in million euro)Self-medication market sales in Europe in 2017, by country
- Sales of analgesics in the self-medication market in Europe in 2017, by country (in million euro)Self-medication market sales of analgesics in Europe in 2017, by country
- Sales of cough and cold products in the self-medication market in Europe in 2017, by country (in million euro)Cough and cold self-medication market sales in Europe in 2017
- Sales of digestives and intestinal remedies in the self-medication product market in Europe in 2017, by country (in million euro)Digestives and intestinal remedies self-medication market sales in Europe 2017
- Sales of self-medication skin treatment products in Europe in 2017, by country (in million euros)Self-medication skin treatment product sales in Europe 2017, by country
- Sales of vitamin and mineral products in the self medication market in Europe in 2017, by country (in million euro)Self-medication: sales of vitamins and minerals in Europe 2017
- Market value of self-medication drugs in Italy from 2014 to 2017 (in million euros)Italy: market value of self-medication drugs 2014-2017
- Sales revenue of self-care medicines in the Netherlands in 2017, by purchase channel (in million euros)Sales revenue of self-care medicines in the Netherlands 2017, by purchase channel
- Employment
The most important statistics
- Pharmaceutical employment in selected European countries in 2017Employment in European pharmaceutical industry by country 2017
- Total pharmaceutical employment in EFPIA countries from 1990 to 2018Employment in EFPIA pharmaceutical industry 1990-2018
- Employment in pharmaceutical products and preparations manufacturing in the United Kingdom from 2008 to 2017 (in 1,000s)Pharmaceutical manufacturing employment in the United Kingdom 2008-2017
- Number of employees in biotechnology companies, split by private or public sector in Switzerland from 2012 to 2017Switzerland: number of employees in biotech companies 2012-2017
- Number of employees in the pharmaceutical industry in Germany from 2010 to 2016Pharmaceutical industry: number of employees in Germany 2010-2016
- Number of employees in the pharmaceutical industry in Belgium from 2014 to 2017Number of employees in the pharmaceutical industry in Belgium 2014-2017
- Number of employees of pharmaceutical companies in France in 2014, by region of residenceNumber of employees of pharmaceutical companies by region France 2014
- Number of employees in the pharmaceutical industry in Italy between 2000 and 2018Number of employees in the pharmaceutical industry in Italy 2000-2018
- Clinical Trials
The most important statistics
- Distribution of European clinical and phase III pipeline in 2013, by indicationDistribution of European clinical and phase III pipeline 2013 by indication
- Number of clinical trials submitted to the European Medicines Agency from European countries from 2005 to 2011Pivotal trials submitted to the European Medicines Agency from Europe 2005-2011
- Number of patients per clinical trial in selected European countries from 2005 to 2011Patients in clinical trials in selected European countries 2005-2011
- Number of applications to conduct a clinical trial submitted to BfArM and PEI* in Germany from 2009 to 2017Clinical trial conduct applications in Germany 2009-2017
- Number of clinical trials authorized by the competent authority in Italy from 2003 to 2017Italy: number of clinical trials authorized in Italy 2003-2017
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Highest acceptable price for 30 day supply of generic drugs by U.S. consumers 2014
- U.S. total vs. generic dispensed prescription numbers 2017, by formulation
- Locations where U.S. consumers purchase prescription drugs 2014, by generation
- Saving of U.S. costs through generic nervous system pharmaceuticals 2004-2013
- U.S. costs saved through generics by therapy 2004-2013
- Share of prescriptions by drug type in public drug plans Canada 2011-2017
- Share of drug costs by type in public drug plans Canada 2011/12 to 2016/17
- Saving of U.S. costs through generic cardiovascular pharmaceuticals 2004-2013
- Canadian prices for top generic molecules 2016
- Generic drug cost change for Canada 2016-2018
- Adjusted and unadjusted generic prescription growth in U.S. 2013-2017
- Generic drug savings by top drug in Canada's public drug plans 2012/2013
- Growth in prescriptions of select drugs in Canada's public drug plans 2013/2014
- Top generic entry drug savings in Canada by public drug plan 2012/2013
- Foreign-to-Canadian generic drug price ratios by OECD country as of 2016
- Accumulation U.S. costs saved through generic pharmaceuticals 2004-2013
- Canadian drug generic to brand drug price ratios quarterly 2010-2016
- Generic drugs revenue in prescribed drug market in India 2008-2015
- Prescriptions per active beneficiary in Canada by public drug plan 2013/2014
Studies
- Generics and biosimilars
- Trends in Retail Prices of Brand Name Prescription Drugs Widely Used by Older Americans: 2...
- 2018 Generic Drug Access & Savings in the United States
- Prescription Cost Analysis, England 2018
- Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans: 2006 to 2015
- Canadian pharmaceutical industry
- 2018 National Progress Report
- A Pan-Canadian Analysis of Prescription Drug Insurance Coverage (2017)
- Express Scripts 2017 Drug Trend Report
- Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans, 2006 to 2013
- Prescribed Drug Spending in Canada, 2018
- 2017 Generic Drug Access & Savings in the United States
- Pharmaceutical Manufacturer Payments and Opioid Prescribing Patterns in New York State
- Pan-Canadian Trends in the Prescribing of Opioids and Benzodiazepines, 2012 to 2017
- Drug Use Among Seniors in Canada, 2016
Statistics on "Pharmaceutical trends in Europe"
- Turnover of leading pharmaceutical markets in Europe in 2017 (in million euros)
- Turnover of pharmaceutical markets in Central and Eastern Europe in 2017 (in million euros)
- Share of breakdown of pharmaceutical price structure in Europe in 2016*
- Value Added Tax (VAT) rate on over-the-counter (OTC) drugs in Europe in 2018, by country*
- Value Added Tax (VAT) rate on prescription-only drugs in Europe in 2018, by country
- Share of GDP expenditure on research and development in the EU-28 countries from 2000 to 2017*
- Pharmaceutical research and development spending in selected European countries in 2017 (in million euros)
- Annual growth of pharmaceutical R&D spending in Europe and the U.S. between 2004 and 2018
- Market share of generics in selected European countries as of 2017
- Leading 18 European pharmaceutical companies by retail sales in 2015 (in billion U.S. dollars)
- Leading pharmaceutical and biotechnology companies in Europe in 2015, based on market value (in million U.S. dollars)
- Leading European pharmaceutical companies by spending on research and development in 2015 (in million U.S. dollars)
- Leading European pharmaceutical companies by investment in research and development in 2014 (in million U.S. dollars)
- Pharmaceutical production value of EFPIA members from 1990 to 2018 (in million euros)
- Pharmaceutical research and development spending of EFPIA members from 1990 to 2018 (in million euros)
- Sales in the self-medication market in selected European countries in 2017 (in million euro)
- Sales of analgesics in the self-medication market in Europe in 2017, by country (in million euro)
- Sales of cough and cold products in the self-medication market in Europe in 2017, by country (in million euro)
- Sales of digestives and intestinal remedies in the self-medication product market in Europe in 2017, by country (in million euro)
- Sales of self-medication skin treatment products in Europe in 2017, by country (in million euros)
- Sales of vitamin and mineral products in the self medication market in Europe in 2017, by country (in million euro)
- Market value of self-medication drugs in Italy from 2014 to 2017 (in million euros)
- Sales revenue of self-care medicines in the Netherlands in 2017, by purchase channel (in million euros)
- Sales revenue of self-care medicines in supermarkets in the Netherlands in 2017, by product segment (in million euros)
- Pharmaceutical employment in selected European countries in 2017
- Total pharmaceutical employment in EFPIA countries from 1990 to 2018
- Employment in pharmaceutical products and preparations manufacturing in the United Kingdom from 2008 to 2017 (in 1,000s)
- Number of employees in biotechnology companies, split by private or public sector in Switzerland from 2012 to 2017
- Number of employees in the pharmaceutical industry in Germany from 2010 to 2016
- Number of employees in the pharmaceutical industry in Belgium from 2014 to 2017
- Number of employees of pharmaceutical companies in France in 2014, by region of residence
- Number of employees in the pharmaceutical industry in Italy between 2000 and 2018
- Distribution of European clinical and phase III pipeline in 2013, by indication
- Number of clinical trials submitted to the European Medicines Agency from European countries from 2005 to 2011
- Number of patients per clinical trial in selected European countries from 2005 to 2011
- Number of applications to conduct a clinical trial submitted to BfArM and PEI* in Germany from 2009 to 2017
- Number of clinical trials authorized by the competent authority in Italy from 2003 to 2017
- What is the most you would be willing to pay out-of-pocket for a 30-day supply of generic prescription drugs?
- Number of dispensed total vs. generics prescriptions in the U.S. in 2017, by formulation (in millions)
- Locations where consumers purchase prescription drugs in the United States in 2014, by generation
- Cost savings through nervous system generic medicine in the United States from 2004 to 2013 (in million U.S. dollars)
- Distribution of cost savings through generics in the United States in the period 2004-2013, by therapeutic area
- Share of prescriptions by drug type in select public drug plans in Canada from 2011/2012 to 2016/2017*
- Share of drug costs by type in select public drug plans in Canada from 2011/2012 to 2016/2017
- Cost savings through cardiovascular generic medicine in the United States from 2004 to 2013 (in million U.S. dollars)
- Canadian prices for leading generic drugs as of 2016 (in Canadian dollars)*
- Generic drug cost growth for Canada from 2016 to 2018
- Adjusted and unadjusted generics prescription volume growth in the U.S. from 2013 to 2017
- Total generic drug savings in Canadian public drug plans in 2012/2013, by top drug (in million Canadian dollars)*
- Growth in prescriptions of select prominent drugs in Canada's public drug plans in 2013/2014 compared to 2012/2013*
- Savings for top 5 generic entry drugs in select Canadian drug plans in 2012/2013 (in 1,000 Canadian dollars)
- Average foreign-to-Canadian generic drug price ratios by OECD country as of 2016*
- Accumulated cost savings through generics in the United States in the period 2004-2013 (in billion U.S. dollars)
- Average generic-to-brand drug price ratios in Canada from Q1 2010 to Q4 2016*
- Revenue of generic drugs in the prescribed drug market in India from 2008 to 2015 ( in billion U.S. dollars)
- Average number of prescriptions per active beneficiary in select Canadian public drug plans in 2013/2014
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Please log in to access our additional functions
Register in seconds and access exclusive features.
Basic Account
|
Instant Access
Premium Account
| ||
|---|---|---|---|
Our services
Click the question mark for further information | Free |
$49 per month* | |
| Basic statistics | |||
| Premium statistics | |||
|
Graph download
| |||
| Download PDF | |||
|
Excel download
| |||
| Register | Purchase now | ||
*Duration: 12 months, billed annually, single license
Yes, let me download!
...and make my research life easier.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.